Drug Information Archives - Page 2 of 61 - Oncology Nurse Advisor

Drug Information

US Food and Drug Administration

Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer

The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer. Herceptin Hylecta is a combination of trastuzumab, an HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase used to increase the dispersion and absorption of coadministered drugs when administered subcutaneously. The product contains the same active ingredient…

Next post in Leukemia